Multiple sclerosis (MS) is a complex disease of the central nervous system affecting roughly one in a thousand in most western countries with a female predominance of about 2:1 (Rosati, 2001). There is a well established consensus on the presence of a genetic component in MS. Monozygotic female twins have a 170-fold increase in susceptibility whereas kinship through adoption does not affect the risk of disease (Dyment et al., 2004) . This has motivated great efforts to identify risk alleles; however until 2007 the only region repeatedly associated to MS was the Human leukocyte antigen (HLA) gene complex.
Eventually, recent collaborative efforts have confirmed an increasing number of susceptibility loci outside of the HLA-region. The first single nucleotide polymorphisms (SNPs) to be associated with MS at genome wide significance were located in IL7R and IL2RA (Hafler et al., 2007; Lundmark et al., 2007) . Furthermore, a recent study by the International Multiple Sclerosis Genetics Consortium (IMSGC) on the genetic overlap between MS and type 1 diabetes confirmed two additional associated SNPs located in CLEC16A and CD226 (2008) . A third SNP located in the SH2B3 gene almost reached genome wide significance and was included in this study.
Whereas genetic influence on the risk of MS is well established by genetic epidemiology, it is less clear whether disease course characteristics are also influenced by genes (Jensen et al.) . MS disease course is indeed highly variable and is usually sub-categorized into relapsing remitting (RR), primary progressive (PP) and secondary progressive (SP) courses. About 90% of MS patients have a bout onset disease (RRMS) with stable periods between relapses before most of them eventually convert into SPMS within two to three decades. Roughly 10% experience PPMS i.e. a relapse-free worsening from disease onset. Within each disease course the rate of progression is variable, however PPMS generally implies faster disabling (Miller and Leary, 2007) . The Expanded Disability Status Scale (EDSS) (Kurtzke, 1983) is the most widely used disability scale in MS and its development as a function of time provides a measure of severity. Patients are graded from 0 (no clinical symptoms) to 10 (death due to MS) on the EDSS based on a clinical examination.
The aim of this study was to test the hypothesis that genotypes of the newly established non-HLA risk genes influence not only course but also the way the disease develops. For this purpose we used a large, ethnically homogenous patient base derived from two Scandinavian clinics and genotypes of five non-HLA genes: IL7R, IL2RA, CLEC16A, CD226 and SH2B3. E-mail address: wangko.lundstrom@ki.se (W. Lundström).
